OncologyOnline.net

Oncology Xagena

Search results for "Advanced non-small cell lung cancer"

A study, led by Canadian researchers, has demonstrated that Erlotinib ( Tarceva ) increases survival in patients with advanced non-small cell lung cancer who typically have no other treatment options. ...


According to Researchers from Dana-Farber Cancer Institute in Boston, Tarceva ( Erlotinib ), a tyrosine kinase inhibitor, showed encouraging activity with relatively tolerable side effects in elderly, ...


A phase II study is assessing the safety and efficacy of Sunitinib ( Sutent ) in patients with advanced non-small cell lung cancer ( NSCLC ) that had progressed following standard therapy. “ This ...


Researchers evaluate the effectiveness of a new antitumoral therapy by looking at how tumors respond to it. But in the case of advanced non-small cell lung cancer ( NSCLC ), there may be a better way ...


Results of the Southwest Oncology Group study, led by UC Davis Cancer Center researchers have shown that adding Bortezomib ( Velcade ) to a standard chemotherapy regimen of Gemcitabine and Carboplati ...


AstraZeneca announced today that it has withdrawn the regulatory submissions for the use of ZACTIMA ( Vandetanib ) 100mg in combination with chemotherapy in patients with advanced non-small cell lung ...


Phase IV lung cancer study has confirmed the safety and outstanding efficacy benefit of Bevacizumab-based therapy in advanced non-small cell lung cancer ( NSCLC ) in a real world setting.The SAiL stud ...


New results from a retrospective study suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ), have anti-cancer effects in a small subset of patients wit ...


Results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent Trastuzumab ( Herceptin ), have anti-cancer effects in a small subset ...


Erlotinib ( Tarceva ) is FDA-approved for the first-line treatment of EGFR mutant non-small cell lung cancer ( NSCLC ), with a median progression free survival ( PFS ) of 10.4 months. Nivolumab, a f ...


Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3 ( LL3 ) has compared Afatinib with Cisplatin / Pemetrexed in 345 patients recrui ...


The LUME-Lung 1 trial has demonstrated a significant overall survival advantage for Nintedanib ( Vargatef ) plus Docetaxel ( Taxotere ) compared with placebo plus Docetaxel as second-line therapy for ...


Positive results from two phase II studies that evaluated the investigational cancer immunotherapy Atezolizumab ( anti-PDL1; MPDL3280A ) in people with advanced non-small cell lung cancer ( NSCLC ) we ...


New data from KEYNOTE-001, a phase 1b study evaluating Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in naïve and previously-treated patients with advanced non-small cell lung cancer ( NSCLC ) wer ...


Results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in p ...